P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study

Drug Safety

Volumn 38, Issue 7, 2015, Pages 651-659

  Daud, Aizati N A ^a   Bergman, Jorieke E H ^b   Bakker, Marian K ^b   Wang, Hao ^a   Kerstjens Frederikse, Wilhelmina S ^b   de Walle, Hermien E K ^b   Groen, Henk ^b   Bos, Jens H J ^a   Hak, Eelko ^a   Wilffert, Bob ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CIMETIDINE; CITALOPRAM; DOXYCYCLINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MORPHINE; MULTIDRUG RESISTANCE PROTEIN; NEUROLEPTIC AGENT; OMEPRAZOLE; PANTOPRAZOLE; PAROXETINE; PRESCRIPTION DRUG; QUETIAPINE; RANITIDINE; RISPERIDONE; SERTRALINE;

ADULT; ARTICLE; CONGENITAL MALFORMATION; ENZYME SPECIFICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATERNAL AGE; POPULATION; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REGISTER; RISK FACTOR; TERATOGENESIS; TERATOGENICITY; ABNORMALITIES, DRUG-INDUCED; ADVERSE EFFECTS; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLASSIFICATION; DRUG INTERACTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MATERNAL EXPOSURE; METABOLISM; NETHERLANDS; ODDS RATIO; PLACENTA; RISK ASSESSMENT; TRANSPORT AT THE CELLULAR LEVEL;

ABNORMALITIES, DRUG-INDUCED; BIOLOGICAL TRANSPORT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MATERNAL EXPOSURE; NETHERLANDS; ODDS RATIO; P-GLYCOPROTEIN; PLACENTA; PREGNANCY; PRESCRIPTION DRUGS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84933673643     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0299-3     Document Type: Article

References (34)

1. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle HEK, De Jong-Van Den Berg LTW. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG. 2006;113:559–68.
2. Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20:895–902.
3. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004;191:398–407.
4. Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy: effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target. 2012;20:736–63.
5. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55:3–29.
6. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22:400–10.
7. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica. 2008;38:802–32.
8. Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett. 2005;156:319–29.
9. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today. 2007;12:833–7.
10. Rubinchik-Stern M, Eyal S. Drug interactions at the human placenta: what is the evidence? Front Pharmacol. 2012;3:1–7.
11. European Surveillance of Congenital Anomalies (EUROCAT). EUROCAT guide 1.3 and reference documents. Instructions for the registration and surveillance of congenital anomalies. 2005. Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf. Accessed 27 Oct 2014.
12. Visser ST, Schuiling-Veninga CC, Bos JH, de Jong-van den Berg LTW, Postma MJ. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res. 2013;13:285–92.
13. Schirm E, Tobi H, de Jong-van den Berg LTW. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol. 2004;57:737–41.
14. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci. 2006;27:501–17.
15. Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21:152–61.
16. Akamine Y, Yasui-Furukori N, Ieiri I, Uno T. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs. 2012;26:959–73.
17. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, et al. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther. 2005;78:123–31.
18. Ceccaldi P-F, Gavard L, Mandelbrot L, Rey E, Farinotti R, Treluyer J-M, et al. Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int. 2009;2009:726593.
19. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol. 2005;69:1869–78.
20. May K, Minarikova V, Linnemann K, Zygmunt M, Kroemer HK, Fusch C, et al. Role of the multidrug transporter proteins ABCB1 and ABCC2 in the diaplacental transport of talinolol in the term human placenta. Drug Metab Dispos. 2008;36:740–4.
21. Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS. Opiates inhibit paclitaxel uptake by P-glycoprotein in preparations of human placental inside-out vesicles. Biochem Pharmacol. 2009;78:1272–8.
22. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 2006;27:602–9.
23. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta. 2005;26:268–70.
24. Unadkat JD, Dahlin A, Vijay S. Placental drug transporters. Curr Drug Metab. 2004;5:125–31.
25. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47–54.
26. Van Roon EN, Flikweert S, Le Comte M, Langendijk PNJ, Kwee-Zuiderwijk WJM, Smits P, et al. Clinical relevance of drug-drug interactions: a structured assessment procedure. Drug Saf. 2005;28:1131–9.
27. Muller F, Fromm MF. Transporter-mediated drug–drug interactions. Pharmacogenomics. 2011;12:1017–37.
28. Blumenfeld YJ, Reynolds-May MF, Altman RB, El-Sayed YY. Maternal-fetal and neonatal pharmacogenomics: a review of current literature. J Perinatol. 2010;30:571–9.
29. Prouillac C, Lecoeur S. The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transfer studies. Drug Metab Dispos. 2010;38:1623–35.
30. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803–13.
31. Schirm E, van den Berg P, Gebben H, Sauer P, De Jong-van den Berg L. Drug use of children in the community assessed through pharmacy dispensing data. Br J Clin Pharmacol. 2000;50:473–8.
32. Cousens S, Blencowe H, Stanton C, Chou D, Ahmed S, Steinhardt L, et al. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet. 2011;377:1319–30.
33. European Surveillance of Congenital Anomalies (EUROCAT). EUROCAT prevalence data tables. 2015. Available at: http://www.eurocat-network.eu/ACCESSPREVALENCEDATA/PrevalenceTables. Accessed 12 Dec 2014.
34. Ornoy A, Reece EA, Pavlinkova G, Kappen C, Miller RK. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res C Embryo Today. 2015;105:53–72.